Cardioprotective effects of 2-octynyladenosine (YT-146) in ischemic/reperfused rat hearts

Journal of Cardiovascular Pharmacology

Volumn 57, Issue 2, 2011, Pages 166-173

  Sasamori, Jun ^a   Aihara, Kazuyuki ^a   Uchibori, Takehiro ^a   Takahashi, Atsuo ^a   Takeo, Satoshi ^b   Tanonaka, Kouichi ^b  

^a TOA EIYO LTD   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

adenosine A1 receptor; cardioprotection; protein kinase C; YT 146

Indexed keywords

1,4 DIHYDRO 2 METHYL 6 PHENYL 4 (2 PHENYLETHYNYL) 3,5 PYRIDINEDICARBOXYLIC ACID 5 BENZYL 3 ETHYL ESTER; 2 (1 OCTYNYL)ADENOSINE; 8 (3 CHLOROSTYRYL)CAFFEINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE RECEPTOR BLOCKING AGENT; ALLOXAZINE; CHELERYTHRINE; CREATINE KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CORONARY ARTERY BLOOD FLOW; DRUG ANTAGONISM; DRUG POTENTIATION; ENZYME ACTIVITY; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; LEFT VENTRICULAR DEVELOPED PRESSURE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADENOSINE; ALKYNES; ANIMALS; CARDIOTONIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 79951556519     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e318201c264     Document Type: Article

References (47)

1. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet. 1994;343: 311-322.
2. Kloner RA. Does reperfusion injury exist in humans? J Am Coll Cardiol. 1993;21:537-545. (Pubitemid 23047942)
3. Ely SW, Mentzer RM Jr, Lasley RD, et al. Functional and metabolic evidence of enhanced myocardial tolerance to ischemia and reperfusion with adenosine. J Thorac Cardiovasc Surg. 1985;90:549-556. (Pubitemid 16238047)
4. Olafsson B, Forman MB, Puett DW, et al. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation. 1987;76: 1135-1145. (Pubitemid 17157296)
5. Liu GS, Thornton J, Van Winkle DM, et al. Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart. Circulation. 1991;84:350-356.
6. Garratt KN, Holmes DR Jr, Molina-Viamonte V, et al. Intravenous adenosine and lidocaine in patients with acute myocardial infarction. Am Heart J. 1998;136:196-204. (Pubitemid 28368839)
7. Ross AM, Gibbons RJ, Stone GW, et al. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (Amistad-II). J Am Coll Cardiol. 2005;45:1775-1780. (Pubitemid 40779856)
8. Moser GH, Schrader J, Deussen A. Turnover of adenosine in plasma of human and dog blood. Am J Physiol. 1989;256(4 pt 1):C799-C806.
9. Kogi K, Uchibori T, Aihara K, et al. Pharmacological profile of the 2-alkynyladenosine derivative 2-octynyladenosine (YT-146) in the cardiovascular system. Jpn J Pharmacol. 1991;57:153-165.
10. Jordan JE, Zhao ZQ, Sato H, et al. Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J Pharmacol Exp Ther. 1997;280:301-309. (Pubitemid 27171416)
11. Schlack W, Schafer M, Uebing A, et al. Adenosine A2-receptor activation at reperfusion reduces infarct size and improves myocardial wall function in dog heart. J Cardiovasc Pharmacol. 1993;22:89-96. (Pubitemid 23178700)
12. Sasamori J, Aihara K, Yoneyama F, et al. Amelioration of ischemia/ reperfusion-induced myocardial infarction by the 2-alkynyladenosine derivative 2-octynyladenosine (YT-146). J Cardiovasc Pharmacol. 2006; 47:614-620. (Pubitemid 44309682)
13. Harada N, Okajima K, Murakami K, et al. Adenosine and selective A2a receptor agonists reduce ischemia/reperfusion injury of rat liver mainly by inhibiting leukocyte activation. J Pharmacol Exp Ther. 2000;294: 1034-1042. (Pubitemid 30666856)
14. Hinschen AK, Rose'Meyer RB, Headrick JP. Adenosine receptor subtypes mediating coronary vasodilation in rat hearts. J Cardiovasc Pharmacol. 2003;41:73-80. (Pubitemid 36015058)
15. Maddock HL, Mocanu MM, Yellon DM. Adenosine A3 receptor activation protects the myocardium from reperfusion/reoxygenation injury. Am J Physiol Heart Circ Physiol. 2002;283:H1307-H1313.
16. Cargnoni A, Ceconi C, Boraso A, et al. Role of A2a receptor in the modulation of myocardial reperfusion damage. J Cardiovasc Pharmacol. 1999;33:883-893. (Pubitemid 29242770)
17. Reid EA, Kristo G, Yoshimura Y, et al. In vivo adenosine receptor preconditioning reduces myocardial infarct size via subcellular ERK signaling. Am J Physiol Heart Circ Physiol. 2005;288:H2253-H2259. (Pubitemid 40604113)
18. Bullough DA, Magill MJ, Firestein GS, et al. Adenosine activates A2 receptors to inhibit neutrophil adhesion and injury to isolated cardiac myocytes. J Immunol. 1995;155:2579-2586.
19. Cronstein BN, Daguma L, Nichols D, et al. The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O22 generation, respectively. J Clin Invest. 1990;85:1150-1157. (Pubitemid 20123757)
20. Yang Z, Day YJ, Toufektsian MC, et al. Myocardial infarct-sparing effect of adenosine A2a receptor activation is due to its action on CD4+ T lymphocytes. Circulation. 2006;114:2056-2064. (Pubitemid 44706882)
21. Rork TH, Wallace KL, Kennedy DP, et al. Adenosine A2a receptor activation reduces infarct size in the isolated, perfused mouse heart by inhibiting resident cardiac mast cell degranulation. Am J Physiol Heart Circ Physiol. 2008;295:H1825-H1833.
22. Finegan BA, Lopaschuk GD, Gandhi M, et al. Inhibition of glycolysis and enhanced mechanical function of working rat hearts as a result of adenosine A1 receptor stimulation during reperfusion following ischae-mia. Br J Pharmacol. 1996;118:355-363. (Pubitemid 26149283)
23. Zucchi R, Yu G, Ghelardoni S, et al. A3 adenosine receptor stimulation modulates sarcoplasmic reticulum Ca2+ release in rat heart. Cardiovasc Res. 2001;50:56-64. (Pubitemid 32244385)
24. Kuno A, Critz SD, Cui L, et al. Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion. J Mol Cell Cardiol. 2007;43:262-271. (Pubitemid 47315714)
25. Schulte G, Fredholm BB. Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal. 2003;15:813-827. (Pubitemid 36776656)
26. Xi J, McIntosh R, Shen X, et al. Adenosine A2a and A2b receptors work in concert to induce a strong protection against reperfusion injury in rat hearts. J Mol Cell Cardiol. 2009;47:684-690.
27. Konno T, Murakami A, Uchibori T, et al. Involvement of adenosine A2a receptor in intraocular pressure decrease induced by 2-(1-octyn-1-Yl)adenosine or 2-(6-cyano-1-hexyn-1-Yl)adenosine. J Pharmacol Sci. 2005;97:501-509. (Pubitemid 40628527)
28. Auchampach JA, Rizvi A, Qiu Y, et al. Selective activation of A3 adenosine receptors with N6-(3-Iodobenzyl)adenosine-5#-N-methyl-uronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. Circ Res. 1997;80:800-809. (Pubitemid 27230054)
29. Liu GS, Richards SC, Olsson RA, et al. Evidence that the adenosine A3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardiovasc Res. 1994;28:1057-1061.
30. Tracey WR, Magee WP, Oleynek JJ, et al. Novel N6-substituted adenosine 5#-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. Am J Physiol Heart Circ Physiol. 2003;285:H2780-H2787. (Pubitemid 37443099)
31. Cerniway RJ, Yang Z, Jacobson MA, et al. Targeted deletion of A3 adenosine receptors improves tolerance to ischemia-reperfusion injury in mouse myocardium. Am J Physiol Heart Circ Physiol. 2001;281:H1751-H1758.
32. Guo Y, Bolli R, Bao W, et al. Targeted deletion of the A3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning. J Mol Cell Cardiol. 2001;33:825-830. (Pubitemid 32538994)
33. Dixon AK, Gubitz AK, Sirinathsinghji DJ, et al. Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol. 1996;118:1461-1468. (Pubitemid 26248800)
34. Black RG Jr, Guo Y, Ge ZD, et al. Gene dosage-dependent effects of cardiac-specific overexpression of the A3 adenosine receptor. Circ Res. 2002;91:165-172. (Pubitemid 34827228)
35. Lasley RD, Rhee JW, Van Wylen DG, et al. Adenosine A1 receptor mediated protection of the globally ischemic isolated rat heart. J Mol Cell Cardiol. 1990;22:39-47. (Pubitemid 20107998)
36. Matherne GP, Linden J, Byford AM, et al. Transgenic A1 adenosine receptor overexpression increases myocardial resistance to ischemia. Proc Natl Acad Sci U S A. 1997;94:6541-6546. (Pubitemid 27270721)
37. Auchampach JA, Gross GJ. Adenosine A1 receptors, KAT P channels, and ischemic preconditioning in dogs. Am J Physiol. 1993;264(5 pt 2): H1327-H1336. (Pubitemid 23154115)
38. Lankford AR, Yang JN, Rose'Meyer R, et al. Effect of modulating cardiac A1 adenosine receptor expression on protection with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2006;290:H1469-H1473.
39. Liang BT. Protein kinase C-dependent activation of KAT P channel enhances adenosine-induced cardioprotection. Biochem J. 1998;336:337-343.
40. Nojiri M, Tanonaka K, Yabe K, et al. Involvement of adenosine receptor, potassium channel and protein kinase C in hypoxic preconditioning of isolated cardiomyocytes of adult rat. Jpn J Pharmacol. 1999;80:15-23. (Pubitemid 29271509)
41. Miura T, Liu Y, Kita H, et al. Roles of mitochondrial ATP-sensitive K channels and PKC in anti-infarct tolerance afforded by adenosine A1 receptor activation. J Am Coll Cardiol. 2000;35:238-245. (Pubitemid 30061286)
42. Henry P, Demolombe S, Puceat M, et al. Adenosine A1 stimulation activates delta-protein kinase C in rat ventricular myocytes. Circ Res. 1996;78:161-165.
43. Miyazaki K, Komatsu S, Ikebe M, et al. Protein kinase C epsilon and the antiadrenergic action of adenosine in rat ventricular myocytes. Am J Physiol Heart Circ Physiol. 2004;287:H1721-H1729. (Pubitemid 39313279)
44. Uecker M, Da Silva R, Grampp T, et al. Translocation of protein kinase C isoforms to subcellular targets in ischemic and anesthetic preconditioning. Anesthesiology. 2003;99:138-147. (Pubitemid 36799044)
45. Weinbrenner C, Liu GS, Cohen MV, et al. Phosphorylation of tyrosine 182 of P38 mitogen-activated protein kinase correlates with the protection of preconditioning in the rabbit heart. J Mol Cell Cardiol. 1997;29:2383-2391. (Pubitemid 27404431)
46. Juhaszova M, Zorov DB, Kim SH, et al. Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest. 2004;113:1535-1549. (Pubitemid 39071677)
47. Sakamoto K, Urushidani T, Nagao T. Translocation of HSP27 to sarcomere induced by ischemic preconditioning in isolated rat hearts. Biochem Biophys Res Commun. 2000;269:137-142. (Pubitemid 30440267)